Neoplasms: Clinical Trials

74 trials for Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

74 enrolling by invitation. 74 Phase 2, 16 Phase 1, 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 274Enrolling by invitation 74
Phase 116Enrolling by invitation 16
Phase 310Enrolling by invitation 10

Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms

Trials (filtered) newest first · largest first

All 74 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
CD19/22 CAR-T cells - Acute Lymphobkastic Leukemia, B Cell Lymphoma
Phase 1 / Phase 2Enrolling by invitationMinsk Scientific-Practical Center for Surgery, Transplantation and Hematology172026-10-102026-10-16
Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer
MRG003 (Becotatug Vedotin) - Biliary Tract Neoplasms
Phase 2Enrolling by invitationJiangmen Central Hospital302026-09-222026-10-26
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital732026-09-012026-09-10
Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma
Hypofractionated Radiation Therapy - Anal Cancer
Phase 2Enrolling by invitationUniversity of Vermont Medical Center242026-08-262026-09-15
Photobiomodulation Alone Versus Photobiomodulation Combined With Topical Oral Oxygen Therapy for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Clinical Trial
sirolase xtent laser, blue m gel - Mucositis Oral, Head & Neck Cancer
Phase 1 / Phase 2Enrolling by invitationAssiut University462026-08-152026-10-08
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 2Enrolling by invitationBnai Zion Medical Center122026-06-012026-07-08
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy - Squamous Cell Carcinoma of the Head and Neck
Phase 2Enrolling by invitationZhejiang Provincial People's Hospital302026-05-012026-04-24
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Phase 2Enrolling by invitationSun Yat-sen University422026-04-202026-06-01
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
Phase 2Enrolling by invitationSWOG Cancer Research Network552026-04-132026-10-05
Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
Bronchial Arterial Chemoembolization (BACE), Systemic anti-tumor combination medications - Non-small Cell Lung Cancer(NSCLC)
Phase 2Enrolling by invitationFujian Cancer Hospital202026-04-092026-07-31
VEN+IDAC vs IDAC in AML
Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia)
Phase 2 / Phase 3Enrolling by invitationGuangdong Second Provincial General Hospital2322026-04-012026-04-17
Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
laparoscopic and endoscopic cooperative surgery - Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST)
Phase 2Enrolling by invitationPeking University People's Hospital402026-04-012026-04-30
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
HVA - Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital402026-04-012026-04-08
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) - Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Phase 2Enrolling by invitationSWOG Cancer Research Network502026-03-252026-10-05
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg - Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Phase 2Enrolling by invitationHoag Memorial Hospital Presbyterian392026-03-052026-09-23
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax
Phase 2 / Phase 3Enrolling by invitationFirst Affiliated Hospital of Zhejiang University2672026-03-012026-06-16
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax
Phase 2 / Phase 3Enrolling by invitationFirst Affiliated Hospital of Zhejiang University4502026-03-012026-06-16
RVU120 Rollover Study
RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
Phase 2Enrolling by invitationRyvu Therapeutics SA142025-12-042026-09-17
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
OC-EIEs - Ovarian Cancer
Phase 1 / Phase 2Enrolling by invitationShenzhen Geno-Immune Medical Institute202025-12-012026-11-02
Tau PET Outcomes With Anti-amyloid Immunotherapies
18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild
Phase 2Enrolling by invitationMayo Clinic1352025-11-042026-10-30

Showing 20 of 74. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (8)  ·  Breast Neoplasms (7)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Colorectal Neoplasms (4)  ·  Glioma (4)  ·  Head and Neck Neoplasms (4)  ·  Cholangiocarcinoma (3)  ·  Gallbladder Neoplasms (3)  ·  Multiple Myeloma (3)  ·  Myelodysplastic Syndromes (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Small Cell Lung Carcinoma (3)  ·  Squamous Cell Carcinoma of Head and Neck (3)  ·  Carcinoma, Renal Cell (2)

Broader conditions

Neoplasms by Site (45)  ·  Neoplasms by Histologic Type (41)  ·  Hemic and Lymphatic Diseases (20)  ·  Digestive System Diseases (19)  ·  Neoplasms, Glandular and Epithelial (19)  ·  Digestive System Neoplasms (17)  ·  Hematologic Diseases (16)  ·  Immune System Diseases (13)  ·  Leukemia (13)  ·  Carcinoma (12)  ·  Immunoproliferative Disorders (12)  ·  Lymphoproliferative Disorders (12)  ·  Gastrointestinal Diseases (11)  ·  Gastrointestinal Neoplasms (10)

Interventions

Carboplatin (3)  ·  Cisplatin (3)  ·  Radiotherapy (3)  ·  130-nm albumin-bound paclitaxel (2)  ·  Azacitidine (2)  ·  Dexamethasone (2)  ·  Induction Chemotherapy (2)  ·  Lenalidomide (2)  ·  Nivolumab (2)  ·  Opiate Substitution Treatment (2)  ·  camrelizumab (2)  ·  carfilzomib (2)  ·  7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1)  ·  Alginates (1)  ·  Bendamustine Hydrochloride (1)

Sponsors

Guangdong Second Provincial General Hospital (3)  ·  First Affiliated Hospital of Zhejiang University (2)  ·  Michael Pulsipher (2)  ·  Peking Union Medical College Hospital (2)  ·  Peking University (2)  ·  SWOG Cancer Research Network (2)  ·  Sir Run Run Shaw Hospital (2)  ·  Sun Yat-sen University (2)  ·  Tomsk National Research Medical Center of the Russian Academy of Sciences (2)  ·  Yingjuan Zheng (2)  ·  Abbisko Therapeutics Co, Ltd (1)  ·  Akiva Mintz (1)  ·  Assiut University (1)  ·  Autolus Limited (1)  ·  Beijing Bio-Targeting Therapeutics Technology Co., Ltd (1)

Countries

China (40)  ·  United States (15)  ·  Russia (5)  ·  Canada (4)  ·  France (4)  ·  Spain (4)  ·  Brazil (3)  ·  Germany (3)  ·  Poland (3)  ·  South Korea (3)  ·  Taiwan (3)  ·  Israel (2)  ·  Italy (2)  ·  Japan (2)  ·  United Kingdom (2)

Top investigators

Vladimir I Chernov, MD, Prof (2)  ·  Adisak Wongkajornsilp, M.D., Ph.D. (1)  ·  Anjali S Advani (1)  ·  Carlos Becerra, MD (1)  ·  Christopher L Anker, MD (1)  ·  Chunyan Chen, MD, PhD (1)  ·  Dong Lin Dong Lin, Bachelor of Medicine(BM) (1)  ·  Guopan Yu, PhD (1)  ·  Hye Ryun Kim (1)  ·  Jiajie Xu (1)  ·  Jinghui Lin Jinghui Lin, Bachelor of Medicine(BM) (1)  ·  Lihong Weng Lihong Weng, Master of Medicine (MM) (1)  ·  Ling Long, PhD (1)

Results publications

PMID 10561263, PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 25040088, PMID 25230595, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 30280641, PMID 30285222, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 32603550, PMID 33446664, PMID 35776909, PMID 36907793, PMID 37124525, PMID 38291578, PMID 38655260, PMID 38713298, PMID 38933450, PMID 39042892, PMID 39177967, PMID 39260670, PMID 40081220, PMID 40140911, PMID 40235787, PMID 40308513

NIH funding

2023 (2), 2018 (1), 2025 (1)